Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Trastuzumab + Chemo in HER2+ Gastric Cancer
NCT03950271Phase 2Active, not recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate at 2 years. Started Jan 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03950271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950271.